報價延遲最少15分鐘:2026/03/02 20:00 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.06 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.59/-0.45
|
|
企業價值
276.92M
|
| 資產負債 |
|
每股賬面淨值
-1.95
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis. |
